Article History
Accepted: 3 February 2021
First Online: 9 March 2021
Declarations
:
: Bayer AG provided funding support for the medical writing assistance received for this manuscript.
: JM has received consulting fees from Alexion, Bayer, BeiGene, Bristol-Myers Squibb, Fosun Kite, Gilead/Kite Pharma, Innovent, Janssen, Juno/Celgene, Kyowa, Pfizer, Pharmacyclics, and Seattle Genetics; research funding from Bayer, Celgene, Genentech, Gilead/Kite Pharma, Incyte, Janssen, Merck, Millennium, Portola, Pharmacyclics, and Seattle Genetics; honoraria from Kyowa and Seattle Genetics; and speaker’s bureau fees from AbbVie, Acrotech/Aurobindo, AstraZeneca, Bayer, BeiGene, Celgene/Bristol-Myers Squibb, Genentech/Roche, Gilead/Kite Pharma, Kyowa, Pharmacyclics/Janssen, Seattle Genetics, and Verastem. GAF reports consultancy and lecturing fees from AbbVie, AstraZeneca, Bayer, Janssen, and Roche. LJN has received honoraria from Bayer, Bristol-Myers Squibb/Celgene, Genentech, Janssen, Kite/Gilead, Novartis, Pfizer, and TG Therapeutics; and research support from Bristol-Myers Squibb/Celgene, Genentech, Janssen, Novartis, Pfizer, and TG Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors provided insight into the development of this manuscript and provided critical review of each draft. All authors read and approved the final manuscript.